UW Study to Use Cellectar Compound
Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today. According to a release,…
Tag Archives: Cellectar Biosciences
Cellectar Earns $2M SBIR Contract
Cellectar Biosciences announced today it is the recipient of the second phase of a National Cancer Institute Fast-Track SBIR contract worth $2 million. According to a release, the money will be used to…
Cellectar Issued New Patent
The U.S. Patent and Trademark Office has awarded Cellectar Biosciences a patent that covers CLR 1603, a phospholipid ether-paclitaxel conjugate, the company announced recently. “This first issued patent under our CLR CTX…
Cellectar Raises $8M in Public Offering
Cellectar Biosciences‘ public offering raised $8 million, the company announced today. “We are pleased with the results of this offering, including the underwriter’s exercise of their full over-allotment option,” Cellectar…
Cellectar Biosciences Nabs SBIR Grant
Cellectar Biosciences announced today it is the recipient of a $2.3 million Fast-Track SBIR grant. According to a release, the money from the National Cancer Institute will help fund development of the…
Cellectar Looks to Raise $3.3M
Cellectar Biosciences today announced it is looking to raise $3.3 million through Wednesday by pricing common stock at $2.20 per share. According to a release, the company looks to use the…
Cellectar CEO to Speak at Investment Conference
Cellectar Biosciences CEO Jim Caruso was chosen to present at the Rodman & Renshaw 17th Annual Global Investment Conference, taking place Sept. 10 in New York City, the organization announced recently. “The…
Jim Caruso to Head Cellectar
Cellectar Biosciences named Jim Caruso to be its new President and CEO, the company announced today. “(Jim) brings a level of energy and commitment, combined with his significant industry experience that…
Cellectar Begins Multiple Melanoma Trial
Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in those with multiple melanoma. “I-131-CLR1404…
Cellectar Applies for Cancer Study
Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has applied to the U.S. Food & Drug Administration to begin a clinical study of a highly-selective,…
